Department of Gynecology and Obstetrics, Kyoto University Graduate School of Medicine, Japan.
Mod Pathol. 2011 Feb;24(2):267-76. doi: 10.1038/modpathol.2010.204. Epub 2010 Nov 12.
Distinguishing primary mucinous ovarian cancers from ovarian metastases of digestive organ cancers is often challenging. Dipeptidase 1 was selected as the candidate novel marker of colorectal cancer based on an analysis of a gene expression microarray. Immunohistochemical analysis indicated that 13/16 ovarian metastases of colorectal cancers, but only 1/58 primary mucinous ovarian cancers, were dipeptidase 1-positive (threshold; ≧25% expression, P<0.0001). Next, five immunohistochemical markers (dipeptidase 1, estrogen receptor-α, cytokeratin 7, cytokeratin 20, and caudal type homeobox 2) were analyzed in combination. In a hierarchical clustering analysis, the mutually exclusive expression of cytokeratin 7 and dipeptidase 1 specifically identified the ovarian metastases of colorectal cancers (P<0.0001). In a decision tree analysis, cytokeratin 7, caudal type homeobox 2, and dipeptidase 1 classified primary mucinous ovarian cancers and ovarian metastases of digestive organ cancers with 90% accuracy. Finally, the five immunohistochemical markers were combined with six preoperative factors (patient's age, tumor size, laterality, serum CEA, CA19-9, and CA125) and combinations were analyzed. Of the 11 factors, 4 (dipeptidase 1, cytokeratin 7, caudal type homeobox 2, and tumor size) were used to generate a decision tree to classify primary mucinous ovarian cancers and metastases of digestive organ cancers with 93% accuracy. In conclusion, we identified a novel immunohistochemical marker, dipeptidase 1, to distinguish primary mucinous ovarian cancers from ovarian metastasis of colorectal cancers. The algorithm using immunohistochemical and clinical factors to distinguish metastases of digestive organ cancers from primary mucinous ovarian cancers will be useful to establish a protocol for the diagnosis of ovarian metastasis.
鉴别原发性卵巢黏液性癌和消化道癌卵巢转移常常具有挑战性。基于基因表达微阵列分析,二肽酶 1 被选为结直肠癌的新型候选标志物。免疫组化分析表明,16 例结直肠癌卵巢转移中有 13 例(阈值;表达≧25%,P<0.0001)为二肽酶 1 阳性,而 58 例原发性卵巢黏液性癌中仅有 1 例(阈值;表达≧25%,P<0.0001)为二肽酶 1 阳性。接下来,分析了 5 种免疫组化标志物(二肽酶 1、雌激素受体-α、细胞角蛋白 7、细胞角蛋白 20 和尾型同源盒 2)的组合。在层次聚类分析中,细胞角蛋白 7 和二肽酶 1 的相互排斥表达特异性地鉴定了结直肠癌的卵巢转移(P<0.0001)。在决策树分析中,细胞角蛋白 7、尾型同源盒 2 和二肽酶 1 可将原发性卵巢黏液性癌和消化道癌的卵巢转移分类,准确率为 90%。最后,将这 5 种免疫组化标志物与术前 6 个因素(患者年龄、肿瘤大小、肿瘤侧别、血清 CEA、CA19-9 和 CA125)相结合进行分析。在这 11 个因素中,4 个(二肽酶 1、细胞角蛋白 7、尾型同源盒 2 和肿瘤大小)被用于生成决策树,以 93%的准确率对原发性卵巢黏液性癌和消化道癌的卵巢转移进行分类。总之,我们鉴定了一种新型免疫组化标志物二肽酶 1,可用于鉴别原发性卵巢黏液性癌和结直肠癌的卵巢转移。使用免疫组化和临床因素的算法来区分消化道癌的转移和原发性卵巢黏液性癌将有助于建立卵巢转移的诊断方案。